Important work emphasising the role of nafld / fibrosis in extrahepatic conditions..

Finally get to meet my good friend Mazen Noureddin, MD, MHSc in person at #ilts2023. Amazing summary of treatment strategies for NASH.. #livertwitter eunice tan Cheng Han Ng Wen Hui Lim Darren Tan ILTS

It’s not too late to register! Click apaslstc2023manila.org to book your slot and catch the latest insights from our international and local faculty! Join us and enjoy the end of summer in the Philippines! See you there! #LiverTwitter APASL News

I'll send to my friend Daniel Huang to treat. There is a certain clinic on Thursdays eagerly awaiting his return!

Are NASH patients disadvantaged on liver transplant wait lists? 🤔

📊 Latest study from The Liver Foundation highlights: Cardiovascular risk up by 43%. Metabolic disorders surge (75%-156%). Kidney disease risk increases by 38%. Cancer risk up by 54%. Call for a holistic healthcare approach. 💪🏥 🔗 Read the full study: cghjournal.org/article/S1542-…

🌍 New study on #NAFLD: From 2010 to 2019, 228M cases, 87,230 deaths, and 1.46M DALYs globally in #elderly. The Western Pacific region hit hardest. Shockingly high prevalence, especially in men. Let's address this urgent global health concern together. onlinelibrary.wiley.com/doi/10.1111/ap…

#GITwitter #LiverTwitter 🔥 #Ultrasound and #MRI is used for screening #HCC... but how is the overall quality of both modality for #HCC screening🤔? Nicholas Syn Daniel Huang Rohit Loomba Mark Muthiah Free to read!: karger.com/ddi/article/41… !

Thanks for the opportunity to collaborate on this piece. from 2010-2019, ⬆️BMI led to: - a 35 % ⬆️ in ☠️ from cancers and 34 % ⬆️ in DALYs - Europe had the greatest number of deaths due to this - Liver cancer is the fastest-growing cause of cancer mortality due to this

📢 Just In!" Defining an approach for therapeutic strategies in MASLD after liver transplantation" | Accelerated fibrosis, high metabolic burden—yet, no regulatory pathway for therapeutics. Bridge the gap for improved post-LT outcomes!🩺🌐pubmed.ncbi.nlm.nih.gov/38088872/ AASLD

Amazing work! Do you think anti viral therapy should be protocolized when discussing HBV cases in tumour board meetings?

Delve into the complex world of #liver fibrosis in #MASLD #MASH. This comprehensive Molecular Aspects of Medicine review by Maurizio Parola & Massimo Pinzani covers everything from pathophysiology to the latest in diagnostics and therapies. A must-read for those seeking depth and detail in liver

HBV antivirals prevent HCC. What % of pts with HBV get an adequate evaluation to assess treatment eligibility based on AASLD criteria? What % receive treatment? 👩‍🦰 disadvantaged! We evaluated 🔼 in 25 centers/>12K pts Journal of Hepatology free link: authors.elsevier.com/a/1j0lccOnAUb9O

Great study Daniel Huang

Understanding and addressing the intertwined factors in #MASLD and #T2D can lead to better management and prevention of cardiometabolic complications. diabetesresearchclinicalpractice.com/article/S0168-…

ILTS Nazia Selzner Valeria Mas, MSc,PhD, FAST Ryan Chadha Manhal Izzy ILTS Vanguard Journal Club ILTS Basic and Translational Research Committee Dr Prashant Bhangui StanfordAbdTxp Rela Hospital @DrEmamaullee

Thanks for organizing this!

Great time in Bali APASL News stc on portal hypertension. Many practical lessons to take home to patients. But the highlight certainly had to be Jasmohan Bajaj and his killer moves! Really great organization by #rinaldilesmana. VCU Stravitz-Sanyal Institute for Liver Disease Jordi Gracia-Sancho Shiv Sarin Ashok Choudhury